Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy

Objective: Data on cellular and humoral immunogenicity after the third dose of anti-SARS-CoV-2 vaccines in patients with immune-mediated rheumatic diseases (IMRDs) are scarce. Herein, we evaluated the adaptive immune response in IMRD patients treated with different immunosuppressive therapies (conve...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed Mohamed, Kauzar, Álvarez-Hernández, María Paula, Jiménez García, Carlos, Guevara-Hoyer, Kissy, Freites, Dalifer, Martínez Prada, Cristina, Pérez-Sancristóbal, Inés, Fernández Gutiérrez, Benjamín, Mato Chaín, Gloria, Rodero, Maria, Rodríguez de la Peña, Antonia, Mulero, Teresa, Bravo, Cecilia, Toledano, Esther, Culebras López, Esther, Mediero Valeros, Beatriz, Pérez Segura, Pedro, Sánchez-Ramón, Silvia, Candelas Rodríguez, Gloria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525269/
https://www.ncbi.nlm.nih.gov/pubmed/37760858
http://dx.doi.org/10.3390/biomedicines11092418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525269/
https://www.ncbi.nlm.nih.gov/pubmed/37760858
http://dx.doi.org/10.3390/biomedicines11092418

Ejemplares similares